(Q34660778)

3 August 2017

1 reference

title

Cytokine therapy or structured treatment interruptions in HIV infection: which is best? (English)

1 reference

3 August 2017

author

Jean-Jacques Parienti

series ordinal

1

object named as

Jean-Jacques Parienti

0 references

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

719-726

1 reference

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Effect of interferon and ribavirin on HIV viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

HIV treatment failure: testing for HIV resistance in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 × 106/l

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.719

21 January 2018

Identifiers

DOI

10.1517/14656566.3.6.719

1 reference

3 August 2017

1 reference